Comparison contrast-enhanced CT with contrast-enhanced US in diagnosing combined hepatocellular-cholangiocarcinoma: a propensity score-matched study

Insights into Imaging

Table 1 Basic clinical and pathological characteristics of patients with cHCC-CCA and HCC

Characteristics	cHCC-CCA (n = 45)	HCC (n = 90)	p value^#
Patients^a
Age (years)	52 ± 9.2	51 ± 11.7	0.630
Sex			0.681
Male	40 (88.9)	82 (91.1)
Female	5 (11.1)	8 (8.9)
Hepatitis status			1.000
HBV (+)	44 (97.8)	87 (96.7)
HCV (+)	1 (2.2)	1 (1.1)
Others	0 (0)	2 (2.2)
AFP level (μg/L)			0.050
0–400	36 (80.0)	57 (63.3)
> 400	9 (20.0)	33 (36.7)
CA 19-9 level (U/mL)			0.029
0–100	40 (88.9)	88 (97.8)
> 100	5 (11.1)	2 (2.2)
Pathological characteristics of the main mass^b
Size (cm)	5.6 ± 3.8	5.5 ± 3.5	0.851
Size (cm)			0.807
≤ 5	26 (57.8)	50 (55.6)
> 5	19 (42.2)	40 (44.6)
Edmondson-Steiner grade			< 0.001
1	1 (2.2)	2 (2.2)
2	3 (6.7)	50 (55.6)
3	11 (24.4)	14 (15.6)
Both 2–3^c	7 (15.6)	23 (25.6)
Not available	23 (51.1)	1 (1.1)

cHCC-CCA combined hepatocellular-cholangiocarcinoma, HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C virus, AFP alpha-fetoprotein, CA 19-9 carbohydrate antigen 19-9
^#Clinical variables were subjected to further logistic regression analysis when p values were < 0.05 in the χ² test or Fisher’s exact test, as appropriate
^aUnless stated otherwise, data in parentheses are counts (percentages)
^bFor the multiple nodules in the liver, only the largest nodule was analyzed in this study
^cThe components of HCC were included in both grades 2 and 3 based on pathological results